drugset / Trial / NCT05397600
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
Timeline
- Start
- 2022-06-22
- Primary completion
- 2024-03-07
- Completion
- 2024-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimatoprost | Other / unclassified | 0.01 % | Other |